MAGEA3 and melanoma: In a phase II clinical study, advanced melanoma patients were treated with ipilimumab combined with autologous moDCs electroporated with TriMix-mRNA (CD40L-, CD70-, and caTLR4-encoding mRNA) and mRNA encoding one of four melanoma-associated antigens (MAGE-A3, MAGE-C2, tyrosinase, or gp100) fused to an HLA-class II targeting signal.